Notice: This company has been marked as potentially delisted and may not be actively trading. aTyr Pharma (LIFE) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period aTyr Pharma initiated with a Buy at Lucid CapitalNovember 20 at 3:13 PM | markets.businessinsider.comCerro de Pasco Resources Announces Amendment to LIFE Offering DocumentNovember 19 at 11:09 AM | globenewswire.comIs aTyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comVERSES Closes Second Tranche of LIFE Offering Bringing Aggregate Funds Raised to $5.2M From Recent OfferingsNovember 15, 2024 | globenewswire.comLogos Global Management LP Adjusts Stake in aTyr Pharma IncNovember 15, 2024 | gurufocus.comRBC Capital Sticks to Its Buy Rating for aTyr Pharma (ATYR)November 9, 2024 | markets.businessinsider.comaTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate UpdateNovember 8, 2024 | markets.businessinsider.comPromising Outlook for aTyr Pharma’s Efzofitimod in Pulmonary Sarcoidosis: Buy Rating AffirmedOctober 30, 2024 | markets.businessinsider.comaTyr Pharma: The Bull Has Finally Come OutOctober 24, 2024 | seekingalpha.comaTyr Pharma IncOctober 22, 2024 | morningstar.comWall Street SWOT: aTyr Pharma stock rides wave of clinical progress amid risksSeptember 29, 2024 | investing.comAdare Pharma’s $16.8M Move: Philadelphia’s New Epicenter for Life Sciences and Job SurgeSeptember 24, 2024 | msn.comZydus Lifesciences To Acquire Sterling Biotech's Active Pharmaceutical Ingredients BusinessSeptember 17, 2024 | msn.comaTyr Pharma: Two 2025 Data Readouts Could Provide Inflection PointSeptember 9, 2024 | seekingalpha.comaTyr Pharma Inc.September 6, 2024 | wsj.comJefferies Initiates Coverage of aTyr Pharma (ATYR) with Buy RecommendationSeptember 6, 2024 | msn.comBuy Rating on aTyr Pharma Anchored by Upcoming Clinical Trials and Strong FinancialsAugust 15, 2024 | markets.businessinsider.comaTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical OperationsAugust 6, 2024 | finance.yahoo.comPinnacle Life Science, a Subsidiary of Aarti Drugs Ltd, Enters the US Market with FDA ApprovalAugust 5, 2024 | msn.comaTyr Pharma Announces Research Study with Stanford MedicineJuly 30, 2024 | finance.yahoo.comIndependent Director of aTyr Pharma Paul Schimmel Buys 10.0% More SharesJuly 26, 2024 | finance.yahoo.comBuy Rating Affirmed: aTyr Pharma’s Positive Clinical Developments and Strategic ExpansionJuly 22, 2024 | markets.businessinsider.comaTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary SarcoidosisJuly 22, 2024 | finance.yahoo.comaTyr Pharma (NASDAQ:LIFE) Stock Crosses Above 200-Day Moving Average of $1.65aTyr Pharma (NASDAQ:LIFE) Stock Price Passes Above 200 Day Moving Average of $1.65June 11, 2024 | marketbeat.comMillionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025June 5, 2024 | investorplace.comSanjay Shukla Purchases 20,000 Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) StockJune 4, 2024 | insidertrades.comInsider Buying: aTyr Pharma, Inc. (NASDAQ:LIFE) Director Purchases 50,000 Shares of StockaTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) Director Timothy Coughlin acquired 50,000 shares of the firm's stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average price of $1.75 per share, with a total value of $87,500.00. Following the completion of the acquisition, the director now owns 56,000 shares in the company, valued at $98,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.June 3, 2024 | marketbeat.comaTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”June 3, 2024 | globenewswire.comShort Interest in aTyr Pharma, Inc. (NASDAQ:LIFE) Declines By 46.0%aTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 343,400 shares, a decline of 46.0% from the April 30th total of 636,200 shares. Based on an average trading volume of 563,900 shares, the short-interest ratio is presently 0.6 days.May 29, 2024 | marketbeat.comaTyr Pharma, Inc.: aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 25, 2024 | finanznachrichten.deaTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 24, 2024 | globenewswire.comaTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International ConferenceMay 15, 2024 | finance.yahoo.comaTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International ConferenceMay 15, 2024 | globenewswire.comaTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisMay 14, 2024 | globenewswire.comaTyr Pharma, Inc. (NASDAQ:LIFE) Short Interest UpdateaTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) was the target of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 636,200 shares, a growth of 66.1% from the April 15th total of 383,100 shares. Based on an average daily volume of 572,400 shares, the short-interest ratio is currently 1.1 days.May 12, 2024 | marketbeat.comStrong Buy Rating for aTyr Pharma as Efzofitimod Shows Promise and Financial StabilityMay 3, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on aTyr Pharma (LIFE)May 3, 2024 | markets.businessinsider.comaTyr Pharma's (LIFE) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of aTyr Pharma in a research note on Friday.May 3, 2024 | marketbeat.comaTyr Pharma (NASDAQ:LIFE) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPSaTyr Pharma (NASDAQ:LIFE - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.11 million.May 3, 2024 | marketbeat.comLIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | investorplace.comaTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateMay 2, 2024 | globenewswire.comaTyr Pharma Insiders Placed Bullish Bets Worth US$514.6kApril 21, 2024 | finance.yahoo.comAtal Incubation Centre - Centre for Cellular and Molecular Biology signs agreement with Thermo Fisher Scientific to advance innovation in IndiaApril 17, 2024 | msn.comaTyr Pharma, Inc. (NASDAQ:LIFE) Shares Sold by Stonepine Capital Management LLCStonepine Capital Management LLC lowered its position in aTyr Pharma, Inc. (NASDAQ:LIFE - Free Report) by 89.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 482,258 shares of the biotechnologyApril 9, 2024 | marketbeat.comaTyr Pharma to Participate in April Investor ConferencesApril 1, 2024 | finance.yahoo.comaTyr Pharma to Participate in April Investor ConferencesApril 1, 2024 | globenewswire.comShort Interest in aTyr Pharma, Inc. (NASDAQ:LIFE) Rises By 167.4%aTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 289,300 shares, an increase of 167.4% from the February 29th total of 108,200 shares. Based on an average daily volume of 521,200 shares, the short-interest ratio is currently 0.6 days.March 28, 2024 | marketbeat.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 26, 2024 | investorplace.comaTyr Pharma (NASDAQ:LIFE) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of aTyr Pharma in a research report on Friday.March 18, 2024 | marketbeat.comRoyal Bank of Canada Cuts aTyr Pharma (NASDAQ:LIFE) Price Target to $16.00Royal Bank of Canada reduced their target price on aTyr Pharma from $19.00 to $16.00 and set an "outperform" rating on the stock in a report on Friday.March 18, 2024 | marketbeat.com Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] LIFE Media Mentions By Week LIFE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIFE News Sentiment▼0.000.46▲Average Medical News Sentiment LIFE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIFE Articles This Week▼51▲LIFE Articles Average Week Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Pacific Biosciences of California News Today Harvard Bioscience News Today PTC Therapeutics News Today Sarepta Therapeutics News Today Thermo Fisher Scientific News Today Agilent Technologies News Today Mettler-Toledo International News Today Waters News Today Illumina News Today Bio-Techne News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIFE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
